Updates Dementia Awareness Course

At Advantage Accreditation, our Curriculum Team is committed to maintaining the accuracy and relevance of our training materials. This is especially critical in the health and social care sector, where advancements in science and procedures continually reshape best practices.

We are pleased to announce that our Level 2 Award in Dementia course has been updated to incorporate new information about the Alzheimer’s drug Lecanemab, which has recently received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK. Lecanemab is a groundbreaking, disease-modifying treatment shown to slow the progression of Alzheimer’s disease by 27% in patients with mild symptoms. This represents a significant advancement in dementia care, offering new hope for those affected by the condition.

However, despite the MHRA’s approval, Lecanemab will not be available through the National Health Service (NHS). The National Institute for Health and Care Excellence (NICE) has determined that the drug’s high cost, alongside the extensive resources required for its administration—such as fortnightly hospital infusions and intensive patient monitoring—makes it unsuitable for public funding. Consequently, Lecanemab will only be accessible via private healthcare providers in the UK.

To ensure our accredited centres and learners remain well-informed, we have revised our dementia awareness course materials to include these key updates. The revised content addresses both Lecanemab’s efficacy in slowing Alzheimer’s progression and the current limitations on its availability within the NHS.

These updates reflect our ongoing commitment to equipping learners with the most current and accurate information on Alzheimer’s treatment and care.

For further information about becoming an accredited training centre or to learn more about our updated course materials, please contact us

Uncategorized